Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

<< Previous

Bullboard Posts

Next >>

Comment by francoisl13on Mar 20, 2024 11:47am

61 Views

Post# 35942911

RE:RE:New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

One thing I forgot to mention is my previous posts is that it will be interesting to know if KNE keeps the patents/IP related to the animal health biofilm applications and ultimately gets some license fees from the STEM buyer and their potential clients.
I hope this will be clarified when they make the sales annoucements.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features